Roivant Provides Positive Update on Graves' Disease Treatment

Details

issued a press release detailing positive results from Immunovant, Inc.'s Phase 2a trial of batoclimab in Graves' Disease. The high dose of batoclimab achieved a 76% response rate and a 56% ATD-free response rate in patients uncontrolled on antithyroid drugs at week 12, indicating a strong correlation between IgG lowering and clinical outcomes. This suggests IMVT-1402 has potential as a best-in-class treatment for Graves' Disease, with an attractive commercial opportunity due to the high unmet need. The U.S. FDA has cleared the Investigational New Drug Application, and a pivotal trial of IMVT-1402 is expected to start by December 31, 2024.

Items reported

Exhibits (1)

About Roivant Sciences Ltd

Roivant Sciences Ltd is a biopharmaceutical company focused on developing and commercializing innovative therapies through a unique model that emphasizes rapid and efficient drug delivery. As a platform company, Roivant Sciences incubates subsidiaries known as 'Vants,' each concentrating on a specific therapeutic area. This model allows Roivant to prioritize development of pharmaceuticals in critical areas, including neurology, oncology, immunology, and others. Roivant’s approach facilitates agility in drug development, enabling each Vant to operate semi-autonomously to accelerate research and commercialization efforts. By leveraging technology and data analytics, Roivant enhances drug discovery processes and optimizes clinical trials. In the pharmaceutical industry, Roivant Sciences represents a forward-thinking entity that addresses unmet medical needs by transforming the traditional paradigms of drug development. Its initiatives have substantial implications for healthcare, potentially altering treatment landscapes and improving patient outcomes globally. Founded in 2014 and headquartered in New York City, Roivant is a notable example of innovation-driven pharmaceutical enterprise in the financial market.